🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leipzig
Clinical trial register · Germany

Clinical Trials in Leipzig, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca26 Eli Lilly and Company22 University of Leipzig21 Novartis Pharmaceuticals20 Janssen Research & Development, LLC17
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Leipzig

511 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Delayed Against Rapid Sequence Induction in Adults With Medical Diseases Undergoing Emergency Endotracheal Intubation.
NCT06940219Intubation in Intensive Care Units
Leipzig University Medical Center
Not applicable
200
Leipzig
2025-06-27
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Ahrensburg, Bendorf, Berlin, Darmstadt, Halle, Hanover, Landsberg, Leipzig
2025-06-27
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
350
Frankfurt, Grevenbroich, Halle, Hanover, Leipzig, Potsdam
2025-06-26
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099Crohn's Disease, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
290
Frankfurt, Grevenbroich, Halle, Hanover, Leipzig, Potsdam
2025-06-26
Recruiting
TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate
NCT06513286Chronic Hepatitis B
Michael Hoelscher
Phase 1/2
81
Frankfurt, Hamburg, Hanover, Leipzig, Munich
2025-06-12
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Berlin, Dresden, Leipzig
2025-06-10
Recruiting
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867Myelodysplastic Syndromes
DrugMomelotinib
GlaxoSmithKline
Phase 2
80
Münster, Dresden, Leipzig
2025-06-05
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839Macular Edema
Boehringer Ingelheim
Phase 2
300
Dresden, Düsseldorf, Leipzig, Mannheim, Münster
2025-06-05
Active, closed
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
DrugsBemnifosbuvir-Ruzasvir·BEM/RZR·Sofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Frankfurt am Main, Leipzig, Hamburg
2025-06-02
Recruiting
Prediction of Blood Pressure Outcomes Following Renal Denervation (PREDICT-RDN)
NCT06845579Uncontrolled Arterial Hypertension
Heart Center Leipzig - University Hospital
Not applicable
90
Mainz, Leipzig
2025-06-01
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Berlin, Brandenburg an der Havel, Dachau, Frankfurt am Main, Kiel, Leipzig, Munich, Ulm
2025-05-27
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,123
Aachen, Trier, Saarbrücken, Leipzig, Jena, Berlin, Hamburg
2025-05-22
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Berlin, Essen, Frankfurt am Main, Hanover, Leipzig, Mainz, Munich, Nuremberg
2025-05-22
Recruiting
Towards a More Standardized Bicuspid Aortic Valve Repair: Rationale and Design of CONTOUR Trial - a Randomized Trial
NCT06869954Bicuspid Aortic Valve (BAV), Aortic Regurgitation Disease
University Hospital Augsburg
Not applicable
100
Augsburg, Frankfurt am Main, Leipzig, Hamburg
2025-05-21
Active, closed
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479Severe Asthma
DrugVerekitug
Upstream Bio Inc.
Phase 2
396
Hamburg, Berlin, Hessen, Leipzig, Bendorf, Mainz
2025-05-21
Recruiting
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
NCT06522737Lymphoma
DrugsDuvelisib·Bendamustine·Gemcitabine
SecuraBio
Phase 3
124
Essen, Goettigen, Halle, Leipzig
2025-05-19
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-19
Recruiting
A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)
NCT06747117Lower Extremity Acute Limb Ischemia, LE ALI
Penumbra Inc.
Observational
300
Cologne, Leipzig, Stuttgart
2025-05-18
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-15
Recruiting
Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression
NCT06967857Attention-Deficit/Hyperactivity Disorder (ADHD), Depression - Major Depressive Disorder
Prof. Dr. Frank Behrens
Phase 2
105
Berlin, Bonn, Frankfurt, Leipzig, München
2025-05-15
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
NCT06990867Acute Ischemic Stroke
Corxel Pharmaceuticals
Phase 2/3
740
Altenburg, Frankfurt, Leipzig, Lübeck, Trier
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Essen, Hamburg, Leipzig, Munich, Oldenburg
2025-05-15
Active, closed
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852Head and Neck Squamous Cell Carcinoma
DrugsBI 770371·Cetuximab·Pembrolizumab
Boehringer Ingelheim
Phase 1
91
Braunschweig, Jena, Leipzig, Ulm
2025-05-14
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Heidelberg, Villingen-Schwenningen, Frankfurt am Main, Mainz, Dresden, Leipzig, Berlin
2025-05-08
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
Bonn, Düsseldorf, Leipzig, Halle, Magdeburg, Berlin
2025-05-06
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
DrugsPelacarsen·Inclisiran
Novartis Pharmaceuticals
Phase 3
340
Stuttgart, Potsdam, Chemnitz, Leipzig, Berlin, Bielefeld, Gelnhausen, Mannheim
2025-04-30
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
905
Bad Mergentheim, Bochum, Essen, Hamburg, Karlsburg, Leipzig, Münster, Oldenburg
2025-04-25
Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869Insomnia Disorder
DrugTasimelteon
Vanda Pharmaceuticals
Phase 3
420
Berlin, Leipzig
2025-04-21
Recruiting
A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)
NCT06656988Peripheral Vascular Diseases, Kidney Diseases
University of Leipzig
Phase 3
1,960
Alsfeld, Bad Krozingen, Bonn, Chemnitz, Flensburg, Frankfurt a.M., Leipzig, München
2025-04-14
Recruiting
VT Ablation in the iCMR
NCT05543798Ventricular Tachycardia
Imricor Medical Systems
Not applicable
64
Leipzig
2025-04-10
Active, closed
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
NCT07108166COPD, Smoking, Tobacco Use
Philip Morris Products S.A.
Not applicable
290
Berlin, Delitzsch, Hanover, Karlsruhe, Leipzig, Neu-Isenburg, Offenbach, Reinfeld
2025-04-02
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475Type 2 Diabetes
Eli Lilly and Company
Phase 2
200
Essen, Leipzig, Münster, Oldenburg
2025-03-28
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel
Daiichi Sankyo
Phase 3
510
Berlin, Bonn, Dresden, Frankfurt am Main, Hamburg, Jena, Leipzig, Nuremberg
2025-03-27
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
565
Freiburg im Breisgau, Würzburg, Frankfurt am Main, Düsseldorf, Merzig, Leipzig, Bad Bentheim, Berlin
2025-03-20
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,000
Erlangen, Düsseldorf, Essen, Saarbrücken, Leipzig, Berlin
2025-03-16
Recruiting
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
NCT06854640Sepsis, Coagulopathy
DrugBAY3389934
Bayer
Phase 1
36
München, Cologne, Dresden, Leipzig
2025-03-12
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
DrugsBMS-986393·Carfilzomib·Pomalidomide·Daratumumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Munich, Hanover, Chemnitz, Leipzig, Magdeburg, Kiel, Berlin, Hamburg
2025-03-12
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
600
Leipzig, Magdeburg, Berlin, Hamburg, Herne
2025-03-10
Recruiting
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
NCT06796907Tumours, Gynecological
DrugsMo-Rez·Dostarlimab·Bevacizumab
GlaxoSmithKline
Phase 1/2
305
Cologne, Leipzig, Mainz, München
2025-03-04
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,088
Bad Bentheim, Bad Doberan, Ratingen, Leipzig, Berlin, Dresden, Hamburg, München
2025-03-03
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Berlin, Chemnitz, Dresden, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, München
2025-02-27
Recruiting
Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial
NCT06533163Glioblastoma Multiforme
BioTex, Inc.
Not applicable
30
Stuttgart, München, Bonn, Lünen, Leipzig, Mannheim
2025-02-17
Active, closed
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293Menstrual Migraine (MM)
DrugAtogepant
AbbVie
Phase 3
468
Erbach im Odenwald, Westerstede, Greifswald, Bielefeld, Ibbenbueren, Siegen, Chemnitz, Leipzig
2025-02-10
Active, closed
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053Asthma
DrugGSK5784283
GlaxoSmithKline
Phase 2
307
Bendorf, Berlin, Darmstadt, Frankfurt, Fürstenwalde, Leipzig, Magdeburg, Mainz
2025-02-10
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Dresden, Hamburg, Leipzig, Mainz, Villingen-Schwenningen
2025-02-06
Recruiting
LEOPARD Training and Validation Data Collection Study
NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
Assistance Publique - Hôpitaux de Paris
Observational
4,500
Aachen, Berlin, Hanover, Jena, Kiel, Leipzig, Münster, Tübingen
2025-02-04
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Frankfurt am Main, Bochum, Mainz, Dresden, Leipzig, Berlin
2025-01-29
Recruiting
EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER
NCT06822036Prostate Cancer (Adenocarcinoma), Blood Loss, Postoperative, Erectile Function
St. Antonius Hospital Gronau
Not applicable
362
Hamburg, Gronau, Leipzig
2025-01-16
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Bad Homburg, Böblingen, Dresden, Ebersberg, Essen, Hamburg, Heidelberg, Leipzig
2025-01-13
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
DrugsAtirmociclib·Ribociclib·Abemaciclib·Palbociclib
Pfizer
Phase 3
1,035
Ravensburg, Erlangen, Dresden, Leipzig, Velbert
2025-01-06
Recruiting
Development of Electroencephalography (EEG) and Magnetoencephalography (MEG) Source Reconstruction With Fast Multipole Method
NCT06471244Healthy
Worcester Polytechnic Institute
Not applicable
30
Ilmenau, Leipzig
2025-01-01
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Cologne, Leipzig, Jena, Aachen, Hamburg, Mainz, Nuremberg, Ulm
2024-12-17
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 2
480
Greifswald, Leipzig, München, Stuttgart
2024-12-16
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Abbott Medical Devices
Not applicable
850
Leipzig, Hanover, Berlin
2024-12-13
Active, closed
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Fluorouracil·Leucovorin
AbbVie
Phase 2
185
Freiburg im Breisgau, Munich, Frankfurt am Main, Leipzig, Hamburg
2024-12-13
Recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619Asthma
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
724
Ahrensburg, Bendorf, Berlin, Delitzsch, Frankfurt, Leipzig, Magdeburg, Mainz
2024-12-12
Active, closed
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
NCT06617429Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 3
129
Hamburg, Leipzig, Munich
2024-12-03
Recruiting
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
48
Dresden, Düsseldorf, Göttingen, Leipzig, Munich
2024-12-03
Recruiting
Peripheral Drivers of Heart Failure Progression - The Prospective PEDAL-HF Study
NCT06656832Heart Failure - NYHA II - IV
University of Leipzig
Not applicable
1,000
Leipzig
2024-11-28
Active, closed
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06465329Non-Small Cell Lung Cancer
DrugsMarlotamig·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
120
Kassel, Göttingen, Leipzig, Aachen
2024-11-18
Active, closed
Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany
NCT06675552Heart Disease, Heart Failure, Cardiovascular Disease, Heart Failure, Systolic
AstraZeneca
Observational
338
Berlin, Erfurt, Gifhorn, Leipzig, Schwerin, Wuppertal
2024-11-15
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Giessen, Immenhausen, Hanover, Essen, Berlin, Leipzig
2024-11-15
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
DrugsBudesonide/Formoterol·Lunsekimig
Sanofi
Phase 2
556
Ahrensburg, Bendorf, Berlin, Frankfurt, Frankfurt am Main, Leipzig, Mainz
2024-11-07
Active, closed
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383Obesity
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
800
Villingen-Schwenningen, Lingen, Cologne, Essen, Leipzig, Oldenburg in Holstein, Hamburg
2024-11-01
Recruiting
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
NCT06675617Type B Aortic Dissection
Intressa Vascular SA
Not applicable
72
Düsseldorf, Frankfurt, Kiel, Leipzig, München, Münster
2024-10-30
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896Scleroderma, Diffuse
DrugsRapcabtagene autoleucel·Rituximab
Novartis Pharmaceuticals
Phase 2
96
Freiburg im Breisgau, Göttingen, Leipzig, Halle, Jena, Berlin, Lübeck, Mainz
2024-10-29
Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168Primary Biliary Cholangitis
Ipsen
Observational
424
Berlin, Frankfurt, Halle, Herne, Homburg, Leipzig, Trier
2024-10-14
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432Solid Tumours
DrugZongertinib
Boehringer Ingelheim
Phase 2
588
Berlin, Giessen, Hamburg, Leipzig, Mannheim, München
2024-10-11
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952Prurigo Nodularis
DrugPovorcitinib
Incyte Corporation
Phase 3
349
Aachen, Bad Bentheim, Berlin, Dortmund, Halle, Hamburg, Heidelberg, Leipzig
2024-10-10
Recruiting
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
NCT06559891Hypertension
SoniVie Inc.
Not applicable
261
Dresden, Erlangen, Frankfurt, Freiburg im Breisgau, Hamburg, Herne, Homburg, Leipzig
2024-10-03
Recruiting
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237Multiple System Atrophy
DrugEmrusolmin
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
350
Beelitz, Dresden, Düsseldorf, Kassel, Leipzig, Marburg, München, Münster
2024-10-02
Recruiting
Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart Failure
NCT06207383Atrial Fibrillation, Persistent, Heart Failure
University Hospital, Geneva
Not applicable
220
Leipzig
2024-10-01
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
DrugLunsekimig
Sanofi
Phase 2
900
Leipzig, Mainz
2024-09-30
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
DrugGSK4532990
GlaxoSmithKline
Phase 2
393
Bochum, Berlin, Kiel, Leipzig, Mainz
2024-09-27
Active, closed
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
DrugSotagliflozin
Lexicon Pharmaceuticals
Phase 3
500
Berlin, Hamburg, Leipzig, München
2024-09-24
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148Geographic Atrophy, Macular Degeneration
Janssen Research & Development, LLC
Phase 2/3
274
Bonn, Göttingen, Hanover, Leipzig, Ludwigshafen am Rhein, Münster, Tübingen
2024-09-19
Active, closed
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 4
500
Bochum, Göttingen, Hanover, Leipzig, Ulm
2024-09-17
Active, closed
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
NCT06243458Low Risk Myelodysplastic Syndromes
DrugRVU120
GCP-Service International West GmbH
Phase 2
41
Düsseldorf, Leipzig, Münster
2024-09-10
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
179
Stuttgart, Frankfurt am Main, Cologne, Leipzig, Jena, Essen, Lübeck, Mainz
2024-09-04
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Frankfurt am Main, Homburg, Leipzig, Lübeck, Berlin
2024-09-04
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
DrugPovetacicept
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Aachen, Berlin, Dresden, Leipzig
2024-08-30
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
DrugsAdriamycin·Taxol·Sacituzumab Govitecan·Doxorubicin
Gilead Sciences
Phase 3
640
Bad Homburg, Düsseldorf, Essen, Hamburg, Hanover, Leipzig, München, Ulm
2024-08-28
Active, closed
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228Asthma
DrugsICS/LABA·Dupilumab
Regeneron Pharmaceuticals
Phase 4
120
Augsburg, Munich, Frankfurt am Main, Koblenz, Lübeck, Berlin, Leipzig, Mainz
2024-08-26
Active, closed
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498Multiple Myeloma
DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib
Kite, A Gilead Company
Phase 3
452
Berlin, Cologne, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Tübingen
2024-08-23
Recruiting
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
NCT06212193Tricuspid Regurgitation, Tricuspid Regurgitation Functional
Innoventric LTD
Not applicable
15
Mainz, Leipzig, Berlin
2024-08-05
Active, closed
Long-term Extension of GTX-102 in Angelman Syndrome
NCT06415344Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 3
255
Hamburg, Leipzig
2024-07-31
Recruiting
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
NCT05373264ADPKD
DrugHydrochlorothiazide
University Medical Center Groningen
Phase 3
300
Berlin, Cologne, Dresden, Leipzig
2024-07-31
Active, closed
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
NCT06440967Hot Flashes
DrugsFezolinetant·Tamoxifen
Astellas Pharma Global Development, Inc.
Phase 3
982
Essen, Bottrop, Dresden, Leipzig, Mönchengladbach, München, Münster, Wolfsburg
2024-07-31
By invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
NCT06475742Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
680
Leipzig, Minden
2024-07-30
Active, closed
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
NCT06355531Progressive Supranuclear Palsy
Ferrer Internacional S.A.
Phase 2
241
Beelitz, Düsseldorf, Leipzig, Munich
2024-07-23
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883Inflammatory Bowel Diseases, Crohn's Disease
DrugZotemtegrast
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Berlin, Dachau, Duisburg, Frankfurt am Main, Halle, Heidelberg, Kiel, Leipzig
2024-07-18
Not yet open
Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging
NCT03865277Head and Neck Squamous Cell Carcinoma
Technische Universität Dresden
Phase 2
276
Freiburg im Breisgau, Heidelberg, Mannheim, Würzburg, Dresden, Leipzig, Berlin, München
2024-07-01
Recruiting
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
NCT06263231Sarcoma,Soft Tissue
DrugsINT230-6·Trabectedin·Pazopanib·Eribulin
Intensity Therapeutics, Inc.
Phase 3
333
Bad Saarow, Leipzig
2024-06-28
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
DrugCladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Ulm, Göttingen, Hanover, Bochum, Düsseldorf, Dresden, Leipzig, Lübeck
2024-06-25
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Head and Neck Squamous Cell Carcinoma
DrugPetosemtamab
Merus B.V.
Phase 3
621
Berlin, Dresden, Essen, Giessen, Greifswald, Hanover, Leipzig, München
2024-06-25
Active, closed
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
DrugsTemodar·Niraparib·Temozolomide
Ivy Brain Tumor Center
Phase 3
450
Heidelberg, Mannheim, Tübingen, Regensburg, Bonn, Chemnitz, Leipzig, Berlin
2024-06-19
Recruiting
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
NCT06122584Prostate Cancer
Drug18F-PSMA-1007
ABX advanced biochemical compounds GmbH
Phase 3
380
Dresden, Düsseldorf, Gronau, Hamburg, Leipzig, München, Münster, Rostock
2024-06-13
Rows per page Showing 101–200 of 511
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-germany/city/leipzig?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 511 of those studies with a site in Leipzig.

How many clinical trials are recruiting in Leipzig?

251 of the 511 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 14 have not yet opened recruitment, 239 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.